Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioNano Genomics Inc (BNGO)
NASDAQ:BNGO
Holding BNGO?
Track your performance easily
BNGO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.19 - $2.27
Previous Close$0.22
Volume4.26M
Average Volume (3M)2.96M
Market Cap
$22.03M
Enterprise Value$32.48M
Total Cash (Recent Filing)$12.00M
Total Debt (Recent Filing)$22.45M
Price to Earnings (P/E)―
Beta3.74
Next Earnings
Mar 06, 2025EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.31
Shares Outstanding101,993,225
10 Day Avg. Volume2,453,558
30 Day Avg. Volume2,955,772
Standard Deviation0.80
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.45
Price to Sales (P/S)0.62
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit3.40
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$1.00Price Target Upside362.96% Upside
Rating ConsensusHold
Number of Analyst Covering3
BioNano Genomics News
PremiumCompany Announcements
Bionano Genomics Sees Growth in OGM Adoption
Bulls Say, Bears Say
Bulls Say
Product DevelopmentBNGO is enhancing its product line by rolling out new laboratory-developed tests for pan-hematological malignancies and genetic diseases from its CLIA lab.
Regulatory ProgressSignificant progress has been made on OGM reimbursement with the acquisition of a CPT code from the American Medical Association for use in cytogenomic genome-wide analysis.
Technology AdvancementsThe continued rollout and upgrade cycle of BNGO's next-generation, higher-throughput Stratys system is set to drive growth.
Bears Say
Financial PerformanceBNGO experienced significant declines in its instrument and services lines.
Revenue GuidanceBNGO again reduced its 2024 revenue guide to $28-30M, below its prior $32-36M, $36-40M, and $37-41M guides earlier this year.
Workforce ReductionBionano will part ways with another 45% of its workforce, expected to reduce its annual cash burn by an additional $25-30M.
---
Ownership Overview
0.44% Insiders
2.58% Mutual Funds
0.75% Other Institutional Investors
94.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNGO FAQ
What was BioNano Genomics Inc’s price range in the past 12 months?
BioNano Genomics Inc lowest stock price was $0.19 and its highest was $2.27 in the past 12 months.
What is BioNano Genomics Inc’s market cap?
Currently, no data Available
When is BioNano Genomics Inc’s upcoming earnings report date?
BioNano Genomics Inc’s upcoming earnings report date is Mar 06, 2025 which is in 69 days.
How were BioNano Genomics Inc’s earnings last quarter?
BioNano Genomics Inc released its earnings results on Nov 13, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.198 by -$0.322.
Is BioNano Genomics Inc overvalued?
According to Wall Street analysts BioNano Genomics Inc’s price is currently Undervalued.
Does BioNano Genomics Inc pay dividends?
BioNano Genomics Inc does not currently pay dividends.
What is BioNano Genomics Inc’s EPS estimate?
BioNano Genomics Inc’s EPS estimate is -$0.14.
How many shares outstanding does BioNano Genomics Inc have?
BioNano Genomics Inc has 101,993,225 shares outstanding.
What happened to BioNano Genomics Inc’s price movement after its last earnings report?
BioNano Genomics Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.198. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of BioNano Genomics Inc?
Among the largest hedge funds holding BioNano Genomics Inc’s share is GMT Capital Corp. It holds BioNano Genomics Inc’s shares valued at 240K.
---
Company Description
BioNano Genomics Inc
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.
---
BNGO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging financial quarter for Bionano, with significant revenue decline and negative gross margins. However, there are positive signs of operational improvement, particularly in cost reductions, increased consumable sales, and progress in clinical research and reimbursement initiatives. The sentiment is mixed with positive strides in some areas countered by financial setbacks.Read More>---
BNGO Stock 12 Month Forecast
Average Price Target
$1.00
▲(362.96% Upside)
Technical Analysis
---